老年食管鳞癌放化疗联合抗PD-1抗体疗效研究

Name: 老年食管鳞癌放化疗联合抗PD-1抗体疗效研究
Creator: 千方医数集科研发现管道
License: CC BY 4.0

基于241例老年食管鳞癌患者，比较放化疗联合抗PD-1抗体与单纯放化疗的疗效与安全性，显示联合治疗未显著改善生存。

Figshare

2026-02-02 更新

表格Esophageal cancerradiotherapyanti-PD-1 antibodychemotherapyelderly patients

Adding anti-PD-1 antibody to definitive chemoradiotherapy in elderly patients with esophageal squamous cell carcinoma: higher intensity does not equate to better outcomes

基本信息

模态

表格

大小

0.013426697 GB

许可

CC BY 4.0

创建/更新时间

2026-02-02

版本

资源简介

老年食管鳞癌放化疗联合抗PD-1抗体疗效研究

【数据集背景】

本数据集源站标题为《Adding anti-PD-1 antibody to definitive chemoradiotherapy in elderly patients with esophageal squamous cell carcinoma: higher intensity does not equate to better outcomes》。配套论文《Adding anti-PD-1 antibody to definitive chemoradiotherapy in elderly patients with esophageal squamous cell carcinoma: higher intensity does not equate to better outcomes》发表于 Annals of Medicine（2026），DOI：10.1080/07853890.2026.2622762。项目资助方：This work was supported by grants from the Basic and Applied Basic Research Foundation of Guangdong Province (2025A1515010951).。源站首次发布：2026-02-02。

【数据内容】

源站原始描述：The benefit of adding anti-PD-1 antibodies to definitive chemoradiotherapy (dCRT) in elderly patients with esophageal squamous cell carcinoma (ESCC) remains uncertain. This study evaluated its efficacy and safety versus dCRT alone. We retrospectively analyzed the patients aged ≥ 70 years with ESCC treated at three academic centers from 2009 to 2023. All patients received first-line dCRT and the study group additionally received anti-PD-1 antibodies (IO group). Propensity score matching (PSM) was…

【数据结构与技术规格】

文件数 2 个，合计 13.43 MB。iann_a_2622762_sm1835.docx：application/vnd.openxmlformats-officedocument.wordprocessingml.document，38.49 KB。数据集 DOI：10.6084/m9.figshare.31230188.v1。

【主题与分类】

源站学科分类：Medicine、Immunology、Biological Sciences not elsewhere classified、Cancer。主题标签：Esophageal cancer、radiotherapy、anti-PD-1 antibody、chemotherapy、elderly patients。

【适用方向】

结构化表格数据可直接用于统计建模、特征工程与队列分析。

【获取与许可】

源站页面：https://tandf.figshare.com/articles/dataset/Adding_anti-PD-1_antibody_to_definitive_chemoradiotherapy_in_elderly_patients_with_esophageal_squamous_cell_carcinoma_higher_intensity_does_not_equate_to_better_outcomes/31230188

使用许可：CC BY 4.0（https://creativecommons.org/licenses/by/4.0/）。

规范引用：Adding anti-PD-1 antibody to definitive chemoradiotherapy in elderly patients with esophageal squamous cell carcinoma: higher intensity does not equate to better outcomes. Taylor & Francis. Cen, Peiying; Chen, Biqi; Zhou, Wenxi; Cheng, Qi; Li, Zimeng; Yi, Chen; et al

原始链接

https://figshare.com/articles/dataset/Adding_anti-PD-1_antibody_to_definitive_chemoradiotherapy_in_elderly_patients_with_esophageal_squamous_cell_carcinoma_higher_intensity_does_not_equate_to_better_outcomes/31230188

访问原始数据